Publications by authors named "Julien Dupin"

Claim this Profile
E
Enhancing confidence in complex health technology assessments by using real-world evidence: highlighting existing strategies for effective drug evaluation.
Alison Antoine, Katia Desroziers, Julien Dupin, David Pérol, Rémy Choquet

BMC Med Res Methodol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.
Ludovic Samalin, Lila Mekaoui, Maud Rothärmel, Anne Sauvaget, Clotilde Wicart, Julien Dupin

Depress Anxiety· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Xavier Pivot, Jean-Philippe Spano, Marc Espie, Christelle Jouannaud, Valerie Pottier, Julien Dupin

Clin Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.
Eric Nguyen-Khac, Pierre Nahon, Olivier Ganry, Hajer Ben Khadhra, Philippe Merle, Julien Dupin

Eur J Gastroenterol Hepatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database.
Olivier Tredan, Marie Laurent, Melina Gilberg, Rim Ghorbal, Alexandre Vainchtock, Julien Dupin

Cancer Inform· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Julien Dupin

EClinicalMedicine· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial.
Youssef Ghazi, Christine Laurent, Julien Dupin, David Pau, Sabine Balouet

Contemp Clin Trials· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, Julien Dupin

Eur J Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis